BMGL vs CUPR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 2/9, indicating severe operational and profitability concerns. Despite a positive revenue growth of 32.20% YoY and a gross margin of 26.29%, the company suffers from catastrophic profitability metrics including a -99.84% profit margin and -194.56% ROE, which undermine sustainable growth. Valuation multiples like Price/Book of 3.96 appear high given the lack of earnings and cash flow visibility, while the stock has lost over 80% of its value in the past year. The absence of Altman Z-Score and intrinsic value estimates further reflects data insufficiency and elevated distress risk.
CUPR shows bearish fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Concerns include weak profitability or high valuation.
Compare Another Pair
Related Comparisons
BMGL vs CUPR: Head-to-Head Comparison
This page compares Basel Medical Group Ltd (BMGL) and Cuprina Holdings (Cayman) Limited (CUPR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.